Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swine.

A short phosphorothioate oligodeoxynucleotide telomere mimic with the sequence 5'-d(TTAGGG)-3', TAG-6, has been shown to inhibit telomerase activity and have antineoplastic and hematopoietic stimulatory properties. In this study, three immature male domestic swine (weighing approximately 40 kg) were administered 200 mg/m2 of TAG-6 by continuous intravascular infusion at rates of 0.48 +/- 0.07 mg/hr for 14 days to evaluate the pharmacokinetics, toxicity, and tissue distribution. There was considerable variability (both within each animal and across animals) observed in the pharmacokinetic data. The plasma half-life (t1/2 appeared to be short enough that it could be assumed that steady state was attained by at least 96 h after the start of the infusion. The t1/2 estimates for the three pigs were 8.96, 109, and 1.97 h (the long t1/2 for pig 2 may be explained by poor parameter estimation due to the variability). The volume of distribution ranged from 9.80 to 51.8 L (0.3-1.4 L/kg), and plasma clearance estimates ranged from 0.33 to 3.46 L/h (5.5-57.7 ml/min). The average plasma concentrations at steady state were 0.845, 0.933, and 0.178 microg/ml (0.44, 0.49, and 0.093 microM) for the three animals. Nearly 30% of the administered dose was cleared through renal excretion by day 7 postinfusion. The distribution of TAG-6 was primarily to the liver and kidney, but the spleen and thyroid accumulated relatively high concentrations of TAG-6. TAG-6 was metabolized to apparently higher molecular weight products, which were observed in the urine. The size periodicity of these apparently higher molecular weight products was in 6-base intervals, which is consistent with the actions of telomerase. The infusion did not produce significant changes in serum chemistry or circulating blood cells, but a decrease in colony-forming unit-granulocyte-monocyte (CFU-GM) colony formation from BM was observed. These data suggest that TAG-6 may be a very specific pharmacophore.

[1]  A. Levin,et al.  Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. , 1997, Antisense & nucleic acid drug development.

[2]  C. Reznikoff,et al.  Urological Survey: Abstracts: Principles of Oncology, and Tumors of Bladder, Penis and UrethraTelomerase Activity: A Biomarker of Cell Proliferation, Not Malignant Transformation , 1998 .

[3]  C. Papadimitriou,et al.  Telomerase activity in precancerous hepatic nodules , 1998, Cancer.

[4]  S. Ross,et al.  The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Abe,et al.  Contiguous Four‐guanosine Sequence in c‐myc Antisense Phosphorothioate Oligonucleotides Inhibits Cell Growth on Human Lung Cancer Cells: Possible Involvement of Cell Adhesion Inhibition , 1997, Japanese journal of cancer research : Gann.

[6]  G. Morin.  The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats , 1989, Cell.

[7]  J. Shay,et al.  Telomerase activity is detected in pancreatic cancer but not in benign tumors. , 1997, Cancer research.

[8]  P. Martiat,et al.  Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. , 1997, Blood.

[9]  P. Iversen,et al.  A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. , 1997, Toxicology and applied pharmacology.

[10]  W. Stec,et al.  Preparation of 35S-labeled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogen phosphonate chemistry. , 1990, Analytical biochemistry.

[11]  H. Soreq,et al.  Use of partially phosphorothioated "antisense" oligodeoxynucleotides for sequence-dependent modulation of hematopoiesis in culture. , 1994, Antisense research and development.

[12]  C. K. Too.  Rapid induction of Jak2 and Sp1 in T cells by phosphorothioate oligonucleotides. , 1998, Antisense & nucleic acid drug development.

[13]  K. Ohyashiki,et al.  Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis. , 1997, Cancer genetics and cytogenetics.

[14]  P. Iversen,et al.  An experimental model for interpreting percutaneous penetration of oligonucleotides that incorporates the role of keratinocytes. , 1998, The Journal of investigative dermatology.

[15]  S. Srinivasan,et al.  Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides , 1995, Journal of clinical laboratory analysis.

[16]  Robert A. Weinberg,et al.  Expression of TERT in early premalignant lesions and a subset of cells in normal tissues , 1998, Nature Genetics.

[17]  W. Novotny,et al.  Inhibition of coagulation by a phosphorothioate oligonucleotide. , 1997, Antisense & nucleic acid drug development.

[18]  Harley Cb,et al.  Telomerase, checkpoints and cancer. , 1997 .

[19]  J. Jackson,et al.  Functional and phenotypic characterization of human peripheral blood stem cell harvests: a comparative analysis of cells from consecutive collections. , 1995, Blood.

[20]  E. Dmitrovsky,et al.  High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. , 1997, Journal of the National Cancer Institute.

[21]  Y. Castier,et al.  The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific. , 1998, The Journal of cardiovascular surgery.

[22]  R. Dahse,et al.  Telomeres and telomerase: biological and clinical importance. , 1997, Clinical chemistry.

[23]  J. Willey,et al.  Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny. , 1996, Oncogene.

[24]  T. Ide,et al.  Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinoma , 1997, International journal of cancer.

[25]  P. Iversen,et al.  In vivo modulation of the rat cytochrome P450 1A1 by double-stranded phosphorothioate oligodeoxynucleotides. , 1995, Toxicology and applied pharmacology.

[26]  David M. Prescott,et al.  Inhibition of telomerase by G-quartet DMA structures , 1991, Nature.

[27]  D. Broccoli,et al.  Telomerase activity in normal and malignant hematopoietic cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Wallwiener,et al.  Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer , 1998, International journal of cancer.

[29]  G. Roos,et al.  Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas , 1996 .

[30]  D. Ecker,et al.  Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). , 1994, AIDS research and human retroviruses.

[31]  D. Ecker,et al.  Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Agrawal,et al.  Effect of different chemically modified oligodeoxynucleotides on immune stimulation. , 1996, Biochemical Pharmacology.

[33]  G. Roos,et al.  Telomeres and telomerase in normal and malignant haematopoietic cells. , 1997, European journal of cancer.

[34]  M. Montalto,et al.  Telomerase activation during the linear evolution of human fibroblasts to tumorigenicity in nude mice. , 1996, Carcinogenesis.

[35]  P. Cannon,et al.  Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. , 1996, The Journal of clinical investigation.

[36]  I. Faraoni,et al.  Development of a novel in vitro chemosensitivity assay: telomerase as a possible marker of tumor cell survival. , 1996, Journal of chemotherapy.

[37]  G. Nabel,et al.  Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. , 1990, Science.

[38]  Y. Pommier,et al.  T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1 , 1995, Antimicrobial agents and chemotherapy.

[39]  B. Monia,et al.  Characterization and modulation of immune stimulation by modified oligonucleotides. , 1997, Antisense & nucleic acid drug development.